Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications

Abstract

The aim of this study was to assess the prognostic role of soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease (HD) both in the achievement of complete remission (CR) and in predicting disease relapse. Between August 1988 and June 1993 sIL-2R serum levels were measured in 174 untreated patients; in 137 of them evaluation was repeated at the end of treatment and in 132 also during the follow-up. Baseline sIL-2R levels (mean+/-standard error) were significantly higher in patients than in 65 healthy control subjects (1842+/-129 U ml(-1) vs 420+/-10 U ml(-10, P< 0.0001). At the end of treatment 135 out of 137 evaluated patients achieved complete response (CR) and their mean sIL-2R serum levels were significantly lower than those at diagnosis (635+/-19 U ml(-1) vs 1795+/-122 U ml(-1), P=0.0001). After a median follow-up of 5 years, sIL-2R remained low in 114 patients in continuous CR, while they increased in 9 out of 12 patients (75%) who relapsed. However, a temporary increase was also observed in six patients (5%) still in CR. Treatment outcome in terms of freedom from progression was linearly related to sIL-2R levels. Our study confirms that patients with untreated HD have increased baseline levels of sIL-2R compared with healthy subjects and that their pretreatment values may be an indication of disease outcome similar to other conventional prognostic factors, such as number of involved sites, presence of B symptoms and extranodal extent.

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index

“…At the present time, it is important to ensure that these analyses can be performed quickly and easily. Serum sIL-2R levels have been clinically investigated in a variety of human diseases such as myelodysplastic syndrome (Ogata et al 1996), Hodgkin's disease (Viviani et al 1998), B-chronic lymphocytic leukemia (Semenzato et al 1987), lymphoblastic lymphoma (Wagner et al 1987), and adult T-cell leukemia/lymphoma (Yasuda et al 1988). However, unexpectedly, there have been few prospective studies that have evaluated the prognostic significance of serum sIL-2R in adult aggressive NHL patients (Niitsu et al 2001;Kono et al 2000).…”

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

“…Therefore, activated T cells, B cells, and parts of lymphoid malignancies display elevated levels of sIL-2R. Except for DLBCL, increased serum sIL-2R levels have been found in patients with lymphoblastic leukemia [9], Hodgkin's disease [10], B chronic lymphocytic leukemia [11], adult T cell leukemia [12], and peripheral T cell lymphoma unspecified [13].…”

Soluble IL-7Rα (sCD127) Inhibits IL-7 Activity and Is Increased in HIV Infection

“…To date, a number of soluble cytokine receptors have been identified, and their mechanisms of release, unique functions, and putative pathophysiological roles have been described (4,5). The first identified soluble cytokine receptor was IL-2Ra (sIL-2Ra), and it has been associated with leukemia disease progression and is a marker of poor prognosis in children with Hodgkin's disease (6). The IL-2Ra gene region, a known autoimmune susceptibility locus, possesses significant allelic heterogeneity related to either susceptibility and risk to MS and type 1 diabetes, and these allelic variants independently correlate with plasma sIL-2Ra concentrations (7).…”